[Association between amytrophic lateral sclerosis and Parkinson's disease].
Alonso-Navarro
Hortensia
H
Ruiz-Ezquerro
Juan José
JJ
Adeva-Bartolomé
Teresa
T
Jiménez-Jiménez
Félix Javier
FJ
D000368:Aged; D000690:Amyotrophic Lateral Sclerosis / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy; D000978:Antiparkinson Agents / Q000008:administration & dosage / Q000627:therapeutic use; D000077465:Cabergoline; D002230:Carbidopa / Q000008:administration & dosage / Q000627:therapeutic use; D015259:Dopamine Agents / Q000008:administration & dosage / Q000627:therapeutic use; D018491:Dopamine Agonists / Q000008:administration & dosage / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D004873:Ergolines / Q000008:administration & dosage / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007980:Levodopa / Q000008:administration & dosage / Q000627:therapeutic use; D018696:Neuroprotective Agents / Q000008:administration & dosage / Q000627:therapeutic use; D010300:Parkinson Disease / Q000150:complications* / Q000175:diagnosis / Q000000981:diagnostic imaging / Q000188:drug therapy; D019782:Riluzole / Q000008:administration & dosage / Q000627:therapeutic use; D013997:Time Factors; D014057:Tomography, X-Ray Computed
D000978:Antiparkinson Agents; D015259:Dopamine Agents; D018491:Dopamine Agonists; D004873:Ergolines; D018696:Neuroprotective Agents; D007980:Levodopa; D019782:Riluzole; D000077465:Cabergoline; D002230:Carbidopa